Alcohol is not known to interact with Taltz (ixekizumab), a humanized interleukin-17A antagonist used to treat adults and children with moderate-to-severe plaque psoriasis, as well as adults with active psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis with objective signs of inflammation.

Analysis of short- and long-term safety data from seven clinical trials of Taltz, which involved 4209 patients with psoriasis, concluded that Taltz has an acceptable safety profile and did not uncover any unexpected safety findings. No interaction between alcohol and Taltz was reported in the analysis.

Dermatologists advise patients with psoriasis to limit alcohol

While Taltz may not interact with alcohol, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) put out guidelines in April 2019 recommending that dermatologists should strongly advise patients with psoriasis to limit alcohol intake. It is thought that consumption of alcohol increases the risk for severe disease in patients with psoriasis. Not only is limiting alcohol recommended in patients with psoriasis to improve skin disease, but it is also recommended to improve overall health.

Studies have revealed links between alcohol consumption and psoriasis, including that people with psoriasis tend to drink more than people who don’t suffer from the condition. People with psoriasis also have about a 60% greater risk of dying from alcohol-related causes compared with similar people who do not have psoriasis.